-
PharmaDrug Advances DMT-Analogue Program For Glaucoma
Thursday, April 7, 2022 - 10:19am | 354PharmaDrug Inc. (OTCQB: LMLLF) (CSE: PHRX) in collaboration with the Terasaki Institute for Biomedical Innovation, has successfully completed the fabrication of a novel medical device capable of delivering sustained, low quantities of undisclosed tryptamine-based pharmaceutical to the front of...
-
PharmaDrug Posts Positive Results For DMT-Analogue Program To Treat Glaucoma
Wednesday, February 23, 2022 - 9:30am | 456Psychedelics and cannabis-focused pharmaceutical company PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) has completed a head-to-head potency comparator study of its two undisclosed DMT-analogue candidates for the treatment of primary open angle glaucoma. What Happened? Following this successful outcome...